Dihydroisoxazole compounds for controlling sea lice
Patent Information
- Application Number
- CN202411143685.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-05-10
- Filing Date
- 2017-05-03
- Publication Date
- 2024-11-29
AI Technical Summary
然而,已观察到对许多这些处理方法的抗性,因此仍需要新的处理方法
Smart Images

Figure CN119033777A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with application date of May 3, 2017, application number 201780027017.8, and invention name “Dihydroisoxazole compounds for controlling sea lice”. Technical Field
[0002] The present invention relates to specific dihydroisoxazole compounds for use in controlling sea lice. The present invention also relates to a method for controlling sea lice by administering a veterinary effective amount of the specific dihydroisoxazole compounds. Background Art
[0003] Sea lice are ectoparasites that feed on the mucus, epidermal tissue and blood of host marine fish (particularly salmon). Sea lice belong to the subclass of copepods. Sea lice can cause significant damage to host fish, particularly they can cause severe fin damage, skin erosion, bleeding and open wounds. In addition, sea lice can cause chronic stress reactions in fish, which in turn can make fish susceptible to other diseases. Sea lice infestation is a major problem in salmon farming and can cause significant economic losses. There are already many treatment methods for controlling sea lice on the market, including bath treatments, such as organophosphates (e.g. dichlorvos and azamethiphos) and pyrethroids (e.g. cypermethrin and deltamethrin), and in-feed treatments, such as avermectins (e.g. ivermectin and avermectin benzoate) and growth regulators (e.g. teflubenzuron). However, resistance to many of these treatments has been observed and there remains a need for new treatments. In particular, there is a need for new treatments that have a long duration of action.
[0004] WO2012 / 158396 discloses certain dihydroisoxazole compounds which are described as being useful for controlling parasitic infestations, including ectoparasites (particularly ticks) and endoparasite infestations. Specific compounds disclosed include the racemic compound N-(2-oxo-2-(prop-2-ynylamino)ethyl)-3-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxamide (Example 47). Summary of the invention
[0005] It has surprisingly been found that a specific dihydroisoxazole compound N-[2-oxo-2-(prop-2-ynylamino)ethyl]-3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxamide is effective against sea lice in fish.
[0006] The present invention provides a compound of formula (I):
[0007]
[0008] or its salts, which are used to control sea lice in fish.
[0009] The present invention also provides a method for controlling sea lice in fish, comprising administering a veterinary effective amount of a compound of formula (I) or a salt thereof to the fish.
[0010] The present invention also provides the use of the compound of formula (I) or a salt thereof in the preparation of a veterinary composition for controlling sea lice in fish.
[0011] The present invention also provides a composition comprising a compound of formula (I) or a salt thereof for use in controlling sea lice in fish.
[0012] In one embodiment of the invention, the fish is salmon.
[0013] In another embodiment of the invention, the compounds of formula (I) are administered orally.
[0014] The present invention also provides a fish feed premix composition, which comprises the compound of formula (I) or a salt thereof.
[0015] The present invention also provides a medicated fish feed, which comprises the compound of formula (I) or a salt thereof. DETAILED DESCRIPTION
[0016] As used herein, the term "control" refers to reducing the number of sea lice, eliminating sea lice and / or preventing further sea lice infestation.
[0017] As used herein, the term "sea lice" refers to all members of the family Caligidae. In particular it includes Lepeotheirus salmonis, Caligus rogercresseyi and Caligus clemensi.
[0018] As used herein, the term "salmon" refers to all fish in the family Salmonidae. In particular, it includes Atlantic salmon (Salmo solar) and Pacific salmon.
[0019] As used herein, the term "veterinarily effective amount" refers to the amount or dosage of a compound of formula (I) or a salt thereof, which provides the desired effect when administered to fish in a single dose or multiple doses.
[0020] The effective amount can be readily determined by one skilled in the art by using known techniques and by observing the results obtained under similar circumstances. In determining the effective amount for veterinary use, many factors are considered, including, but not limited to: the species of fish; the level of sea lice infestation; the response of the fish population; the mode of administration; the bioavailability characteristics of the administered formulation; the dosing regimen selected; the use of concomitant medications; and other relevant circumstances.
[0021] The compound of formula (I) or its salt can be applied to fish by any route having the desired effect, including but not limited to oral administration or application in the form of bath treatment. Oral administration is preferred. More particularly, feed administration is preferred. In one embodiment of the invention, the compound of formula (I) or its salt is orally administered at a daily dose of 1 to 10 mg / kg of fish biomass, preferably at a daily dose of 3 to 7 mg / kg of fish biomass, and most preferably at a daily dose of about 5 mg / kg of fish biomass.
[0022] In one embodiment of the invention, the compound of formula (I) or its salt is applied at the end of the freshwater stage or at the beginning of the seawater stage in fish farming. In one embodiment, the total treatment period during which the compound of formula (I) or its salt is applied is 3 to 14 days, preferably 5 to 14 days, more preferably 5 to 10 days, and most preferably 7 days. During the entire treatment period, the compound of formula (I) or its salt can be applied, for example, every day or once every two days. Preferably, it is applied every day. In a preferred embodiment, it is applied every day for 7 days.
[0023] In a preferred embodiment, the compound of formula (I) or its salt is orally administered for 3 to 14 days at a daily dose of 1 to 10 mg / kg fish biomass. In another preferred embodiment, the compound of formula (I) or its salt is orally administered for 5 to 10 days at a daily dose of 3 to 7 mg / kg fish biomass. In a more preferred embodiment, the compound of formula (I) or its salt is orally administered for 7 days at a daily dose of about 5 mg / kg fish biomass.
[0024] In one embodiment of the present invention, the compound of formula (I) or its salt is applied in medicated fish feed. Fish feed is usually in the form of granules or pellets. Common ingredients of the fish feed granules or pellets include fish meal, fish oil, vegetable protein, carbohydrates and polysaccharides (including mannan, dextran and alginate). In addition, excipients such as pigments, vitamins, minerals and adhesives may also be included. The compound of formula (I) or its salt may be incorporated into the feed before granulation, or the compound of formula (I) or its salt may be coated on the granules or pellets, alone or in the form of a premix. In addition to the active compound, the premix may also contain one or more veterinary acceptable excipients, such as starch, fumed silica, microcrystalline cellulose, lactose and preservatives.
[0025] In one embodiment of the present invention, the compound of formula (I) or its salt is present in the fish feed premix composition in an amount of 5 to 20% (w / w), preferably 10 to 15% (w / w), most preferably about 12.5% (w / w), in each case based on the total weight of the premix.
[0026] In another embodiment of the present invention, the compound of formula (I) or its salt is present in the medicated fish feed in an amount of 0.01 to 2% (w / w), preferably 0.1 to 1% (w / w), more preferably about 0.5% (w / w), in each case based on the total weight of the fish feed.
[0027] Salts of the compounds of the invention, including pharmaceutically acceptable salts, and common methods for preparing them are known in the art. See, for example, P. Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection and Use, (VCHA / Wiley-VCH, 2002); SM Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977.
[0028] Example
[0029] One of ordinary skill in the art can prepare the compounds of formula (I) according to art-recognized techniques and procedures. More specifically, the compounds of formula (I) can be prepared as described in the following preparations and examples. Reagents and starting materials are readily available to one of ordinary skill in the art.
[0030] Preparation 1
[0031]
[0032] 2,2,2-Trifluoro-1-(3,4,5-trichlorophenyl)ethanone
[0033] In N 2Under atmosphere, at 0 ° C, isopropylmagnesium chloride (2M, 230.47mL) was added dropwise to a solution of 5-bromo-1,2,3-trichlorobenzene (100.00g, 384.11mmol) in tetrahydrofuran (1L), and the mixture was stirred at 0 ° C for 2 hours. The mixture was cooled to -5 ° C and ethyl 2,2,2-trifluoroacetate (109.15g, 768.22mmol) was added dropwise. The mixture was then stirred at 25 ° C for 14 hours, quenched with aqueous ammonium chloride solution (1L) and the organic matter was extracted with ethyl acetate (1L×3). The organic layer was dried with sodium sulfate, filtered and concentrated to dryness under reduced pressure. The residue was distilled at 86 ° C at -0.05MPa to give 2,2,2-trifluoro-1-(3,4,5-trichlorophenyl) ethyl ketone, 74% yield (175.00g), as an off-white solid. 1 H NMR (CDCl 3 )δ8.05(s,2H)。
[0034] Preparation 2
[0035]
[0036] Methyl 2-acetylmethylthioacetate
[0037] 2-Methyl mercaptoacetate (200g, 1.88mol, 170.94mL) was added to an ice-cold solution of sodium methoxide prepared from sodium (44.09g, 1.92mol, 45.45mL) and methanol (860mL) under nitrogen, and then 1-chloropropane-2-one (183g, 1.98mol) was added over 30 minutes. The resulting mixture was stirred at 0 to 25°C for 30 minutes, and then stirred at 50 to 60°C for another 30 minutes. The reaction mixture was filtered to remove the precipitate (sodium chloride). After removing the solvent, the residue was poured into cold water and then extracted with ethyl acetate (300mL×2). The extract was washed with brine (100mL), dried over sodium sulfate and concentrated to give a crude material. The crude material was distilled under reduced pressure to give methyl 2-acetylmethylthioacetate (250g, 82% yield) as a yellow oil.
[0038] 1 H NMR (CDCl 3 )δ3.70(s,3H),3.40(s,2H),3.24(s,2H),2.26(s,3H).
[0039] Preparation 3
[0040]
[0041] 3-Acetyl-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester
[0042] Under nitrogen, 2-acetylmethylthioacetic acid methyl ester (50.00g, 308.24mmol) was added to a solution of sodium methoxide (34.69g, 642.17mmol) in methanol (500.00mL) cooled to 0°C, and then cyclohexane-1,2-dione (25.92g, 231.18mmol) was added at 0°C for 15 minutes. The resulting mixture was stirred at 0°C to 25°C for 45 minutes. After the temperature reached 10°C, a solid was precipitated. The reaction mixture was filtered. The filter cake was washed with methanol (50mL) and dried in vacuo to give compound 3-acetyl-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester (127g, 42% yield) as a yellow solid. 1 H NMR (CDCl 3 )δ3.89 (s, 3H), 3.10-2.90 (m, 2H), 2.53 (s, 3H), 1.80-1.60 (m, 3H).
[0043] Preparation 4
[0044]
[0045] 3-[4,4,4-trifluoro-3-hydroxy-3-(3,4,5-trichlorophenyl)butyryl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester
[0046] Lithium bis(trimethylsilyl)amide (1M, 272.77 mL) was added dropwise to a solution of methyl 3-acetyl-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate (50.00 g, 209.82 mmol) in tetrahydrofuran (2.5 L) at -78 °C under a nitrogen atmosphere, and the mixture was stirred at -30 °C for 2 hours. The mixture was cooled to -78 °C and 2,2,2-trifluoro-1-(3,4,5-trichlorophenyl)ethanone (69.86 g, 251.78 mmol) was added. The mixture was stirred at -30 °C for 2 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 10: 1, R f =0.4) shows the progress of the reaction. The mixture was quenched with saturated aqueous ammonium chloride solution (1 L) and extracted with ethyl acetate (1 L × 3). The organic layer was dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure. The residue was recrystallized in hexane (500 mL) and filtered. The solid was washed with hexane (200 mL) and dried under reduced pressure to give 3-[4,4,4-trifluoro-3-hydroxy-3-(3,4,5-trichlorophenyl)butyryl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester (100.00 g, 83% yield) as an off-white solid. 1H NMR (CDCl 3 )δ7.64 (s, 2H), 5.93 (s, 1H), 3.93 (s, 3H), 3.63 (d, J = 16.8Hz, 1H), 3.52 (d, J = 16.8Hz, 1H), 3.10-3.00 (m, 2H).
[0047] Preparation 5
[0048]
[0049] 3-[(Z)-4,4,4-trifluoro-3-(3,4,5-trichlorophenyl)but-2-enoyl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester
[0050] Thionyl chloride (34.60 g, 290.83 mmol) was added dropwise to a mixture of methyl 3-[4,4,4-trifluoro-3-hydroxy-3-(3,4,5-trichlorophenyl)butanoyl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate (100.00 g, 193.89 mmol) and pyridine (61.35 g, 775.55 mmol) in dichloromethane (500 mL) at 0°C, and the mixture was stirred at 25°C for 2 hours. The product was purified by thin layer chromatography (petroleum ether:ethyl acetate=10:1, R f =0.57 and 0.50) show the progress of the reaction. The mixture was quenched with water (50 mL) and extracted with dichloromethane (50 mL×3). The organic layer was washed with sodium bicarbonate aqueous solution (50 mL), dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure to obtain 3-[(Z)-4,4,4-trifluoro-3-(3,4,5-trichlorophenyl)but-2-enoyl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester (80.00 g, 83% yield) as a light yellow solid. 1 H NMR (CDCl 3 .400MHz) δ7.54 (s, 0.37H), 7.33 (s, 1.54H), 7.26 (s, 1H), 3.91 (s, 3H), 3.10-2.90 (m, 4H), 1.80-1.60 (m, 4H).
[0051] Preparation 6
[0052]
[0053] (1S,2S,4S,5R)-1-(3,5-bis(trifluoromethyl)benzyl)-2-((R)-hydroxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine-1-ium bromide
[0054] A mixture of (R)-(6-methoxy-4-quinolyl)-[(2S)-5-vinylquinuclidine-2-yl]methanol (30.00 g, 92.47 mmol) and 1-(bromomethyl)-3,5-bis(trifluoromethyl)benzene (34.07 g, 110.96 mmol) in acetone (500 mL) was stirred at 50° C. for 16 hours. The mixture was purified by thin layer chromatography (ethyl acetate, R f =0.15) shows the consumption of raw materials. The mixture was concentrated under reduced pressure to dryness. The residue was recrystallized from tetrahydrofuran (300 mL) and filtered. The solid was washed with tetrahydrofuran (300 mL), dissolved in dichloromethane (300 mL) and toluene (150 mL), and then concentrated under reduced pressure to dryness. (1S, 2S, 4S, 5R) -1- (3, 5- bis (trifluoromethyl) benzyl) -2- ((R) -hydroxy (6-methoxyquinoline-4-yl) methyl) -5-vinylquinuclidine -1-ium bromide (50.00 g, 77% yield) was obtained as a light yellow solid. 1 H NMR (DMSO-d6, 400MHz) δ8, 83 (d, J = 4.0Hz, 1H), 8.47 (s, 2H). 8.39 (s, 1H), 8.05 (d, J = 9.2Hz, 1H), 7.76 (d, J = 4.4Hz, 1H), 7.54 (dd, J = 9.2Hz, 2. 4Hz, 1H), 7.39 (d, J = 2.4Hz, 1H), 6.90 (d, J = 4.0Hz, 1H), 6.52 (d, J = 3.2Hz, 1H). 5.80-5.60 (m, 1H), 5.55 (d, J = 12.4Hz, 1H). 5.13 (d, J = 17.6Hz, 1 H), 5.03 (d, J = 10.6Hz, 1H), 495 (d, J = 12.4Hz, 1H), 4.40-4.30 (m, 1H), 4.02 (s, 3H), 3.85-3.75 (m, 1H), 3.75-3.65 (m, 1H), 3.45 (t, J = 12.0Hz, 1 H), 3.30-3.20(m, 1H), 2.70-2.60(m, 1H), 2.30-220(m, 1H), 2.20-2.10 (m, 1H), 2.05-1.95 (m, 1H), 1.85-1.75 (m, 1H), 1.49 (t, J=10.8Hz, 1H).
[0055] Preparation 7
[0056]
[0057] 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester
[0058] Hydroxylamine (301.35 mmol, 50% purity) was added dropwise to a mixture of methyl 3-[(Z)-4,4,4-trifluoro-3-(3,4,5-trichlorophenyl)but-2-enoyl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate (50.00 g, 100.45 mmol) and (1S,2S,4S,5R)-1-(3,5-bis(trifluoromethyl)benzyl)-2-((R)-hydroxy(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine-1-ium bromide (6.65 g, 11.05 mmol) in chloroform (1.50 L) at -15°C, followed by the addition of sodium hydroxide (10 M, 30.14 mL) at -15°C. The mixture was then stirred at -15°C for 2 hours. Thin layer chromatography (petroleum ether: ethyl acetate = 10:1, R f =0.48) shows the progress of the reaction. The mixture was quenched with hydrochloric acid (1 M) until pH = 2 and extracted with dichloromethane (1.5 L x 3). The organic layer was dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure to give 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid methyl ester (50.00 g, 87% yield) as an off-white solid. 1H NMR (CDCl 3 )87.62 (s, 2H), 4.54 (d, J = 17.2Hz, 1H), 3.88 (s, 3H), 3.66 (d, J = 17.2Hz, 1H), 3.10-3.00 (m, 2H), 2.95-2.85 (m, 2H), 1.80-1.65 (m, 4H).
[0059] Preparation 8
[0060]
[0061] 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid
[0062] A mixture of methyl 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylate (50.00 g, 97.51 mmol) and lithium hydroxide monohydrate (20.46 g, 487.55 mmol) in methanol (800 mL) and water (200 mL) was stirred at 25° C. for 12 hours. The mixture was purified by thin layer chromatography (petroleum ether:ethyl acetate=10:1, R f =0.08) showed the consumption of starting material. The mixture was acidified with hydrochloric acid (1 M) until pH = 2, and then extracted with dichloromethane (1 L x 3). The organic layer was dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure to give 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid (46.00 g, 85% yield) as an off-white solid. 1 H NMR (DMSO-d 6 )δ7.87 (s, 2H), 4.40-4.20 (m, 2H), 3.00-2.90 (m, 2H), 2.85-2.75 (m, 2H), 1.70-1.55 (m, 4H).
[0063] Preparation 9
[0064]
[0065] tert-Butyl N-[2-oxo-2-(prop-2-ynylamino)ethyl]carbamate
[0066] A mixture of 2-(tert-butoxycarbonylamino)acetic acid (30.00 g, 171.25 mmol), prop-2-yn-1-amine (10.38 g, 188.38 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (78.14 g, 205.50 mmol) and N,N-diisopropylethylamine (66.40 g, 513.75 mmol) in dichloromethane (1.00 L) was stirred at 25° C. for 16 hours. The mixture was purified by thin layer chromatography (petroleum ether:ethyl acetate=1:1, R f =0.26) shows the consumption of raw materials. The mixture was diluted in water (1 L) and extracted with dichloromethane (1 L×3). The organic layer was dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure. The crude material was purified by silica gel chromatography (petroleum ether: ethyl acetate = 10: 1 to 1: 1) to give tert-butyl N-[2-oxo-2-(prop-2-ynylamino)ethyl]carbamate (30.00 g, 74% yield) as an off-white solid.1 H NMR (CDCl 3 ) δ6.48 (brs, 1H), 5.18 (brs, 1H), 4.07 (dd, J=5.2Hz, 2.4Hz, 2H), 3.82 (d, J=5.6Hz, 2H), 2.23 (t, J=2.4Hz, 1H), 1.46 (s, 9H).
[0067] Preparation 10
[0068]
[0069] 2-Amino-N-prop-2-ynyl-acetamide hydrochloride
[0070] A mixture of tert-butyl N-[2-oxo-2-(prop-2-ynylamino)ethyl]carbamate (7.00 g, 32.98 mmol) and hydrochloric acid / dioxane (4 M, 50 mL) in dioxane (50 mL) was stirred at 25° C. for 2 hours. The mixture was purified by thin layer chromatography (petroleum ether:ethyl acetate=1:1, R f =0.04) showed consumption of starting material. The mixture was concentrated to dryness under reduced pressure to give crude 2-amino-N-prop-2-ynyl-acetamide hydrochloride (4.90 g) as an off-white solid, which was used directly in the next step without further purification. 1 H NMR (DMSO-d 6 ) δ 8.87 (brs, 1H), 8.14 (brs, 3H), 3.93 (dd, J = 5.6Hz, 2.4Hz, 2H), 3.53 (s, 2H), 3.18 (t, J = 2.4Hz, 1H).
[0071] Example 1
[0072]
[0073] N-[2-Oxo-2-(prop-2-ynylamino)ethyl]-3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxamide
[0074] A mixture of 3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxylic acid (15.00 g, 30.08 mmol), 2-amino-N-prop-2-ynyl-acetamide (4.90 g, 33.09 mmol, HCl), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (13.72 g, 36.10 mmol) and N,N-diisopropylethylamine (11.66 g, 90.24 mmol) in dichloromethane (500 mL) was stirred at 25° C. for 12 hours. The product was analyzed by thin layer chromatography (petroleum ether:ethyl acetate=3:1, R f =0.30) shows the progress of the reaction. The mixture was diluted in water (500 mL) and extracted with dichloromethane (500 mL×3). The organic layer was washed with brine (500 mL), dried over sodium sulfate, filtered and concentrated to dryness under reduced pressure. The crude material was purified by silica gel chromatography (petroleum ether: ethyl acetate = 10: 1 to 1: 1) to give the corresponding product with 70% ee, which was further purified by supercritical fluid chromatography (SFC) to give N-[2-oxo-2-(prop-2-ynylamino)ethyl]-3-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-4,5,6,7-tetrahydro-2-benzothiophene-1-carboxamide (6.00 g, 34% yield, 99.8% ee) as an off-white solid. 1 H NMR (CDCl 3 ): δ7.62 (s, 2H), 7.05-6.90 (m, 2H), 4.18 (d, J = 4.8Hz, 2H), 4.10 (t, J = 2.4Hz, 2H), 4.06 (d, J = 16.8Hz, 1H) , 3.68 (d, J = 16.8Hz, 1H), 3.10-2.95 (m, 2H), 2.90-2.80 (m, 2H), 2.24 (t, J = 2.4Hz, 1H), 1.90-1.70 (m, 4H).
[0075] LC / MS (m / z): 592 (M+H) + .
[0076] The SFC conditions are as follows
[0077] SFC analysis conditions:
[0078] Instrument: Berger SFC
[0079] Chiralcel OD-3150×4.6mm ID,3um
[0080] Mobile phase: A:CO 2 , B: ethanol (0.05% DEA)
[0081] Gradient: 5% to 40% B in 5 min, hold at 40% for 2.5 min, then 5% B for 2.5 min; Flow rate: 2.5 mL / min
[0082] Wavelength: 220nm
[0083] Column temperature: 35°C
[0084] Retention time: 6.12 min (S-isomer)
[0085] SFC separation conditions:
[0086] Instrument: Thar SFC 200;
[0087] Column:AS250mm*50mm,10um;
[0088] Mobile phase: A: supercritical CO2, B: EtOH, base-EtOH, initial B: 40%, final B: 40%
[0089] Wavelength: 220nm
[0090] Flow rate: 200ml / min
[0091] Column temperature: 38°C;
[0092] Nozzle pressure: 100 bar;
[0093] Nozzle temperature: 40℃;
[0094] Evaporator temperature: 40℃;
[0095] Trimmer temperature: 25℃;
[0096] Retention time: 5.66 min (R-isomer), 5.96 min (S-isomer).
[0097] In vitro activity against copepod larvae of the salmon scab lice (Lepeophtheirus salmonis)
[0098] Sea lice copepod larvae are used to inoculate 96-well plates containing the compound of Example 1 (test compound). The test compound is tested by serial dilution to determine its minimum effective dose (MED). The copepod larvae are contacted with the test compound diluted in seawater for 1 hour. They are then incubated in untreated seawater for 48 hours. If no copepod larvae move within a period of 80 seconds, the efficacy against sea lice is confirmed.
[0099] In this test, the compound of Example 1 showed 100% efficacy at a dose as low as 0.5 ng / ml seawater.
[0100] In vivo activity against Lepeophtheirus salmonis on Atlantic salmon using feed application
[0101] 60 salmon (Atlantic salmon, S. solar) with an average weight of 306.5 g were treated with medicated pellets containing the compound of Example 1 (test compound) at a dose of 5 mg / kg / day for 7 consecutive days. The medicated pellets were prepared as follows: commercial fish feed pellets were dry-coated with a premix containing the test compound to achieve a content of 0.5% (w / w) of the test compound in the fish feed, sealed with 1% fish oil and applied at a 1% feed rate. The treatment was carried out in seawater.
[0102] After treatment, the fish were challenged with copepod larvae (MERL-resistant strain IoA-01) at 35, 100 and 150 days after treatment. During the study, water temperature varied between 7 and 10°C. Fish weight and sea lice counts were assessed at 42, 107 and 157 days after treatment. 30 fish were counted at each sampling time. Efficacy was determined by comparison with a negative control (placebo) group.
[0103] Potency was calculated using the following formula:
[0104] % efficacy = 100 - (100 x mean of treatment group / mean of control group).
[0105] All fish were anesthetized with 2-phenoxyethanol and examined for lice settlement under a dissecting microscope. After counting, the fish were returned to the tank.
[0106] In this test, the compound of Example 1 showed 100% efficacy against challenges carried out 35, 100 and 150 days after treatment.
Claims
1. The compound of the formula: or its salts, for controlling sea lice in fish.
2. The compound or salt thereof for use according to claim 1, wherein the fish is salmon.
3. The compound or salt thereof for use according to claim 1 or claim 2, wherein the compound or salt thereof is administered orally.
4. A method for controlling sea lice in fish, comprising administering to the fish an effective amount of a compound of the formula:
5. The method of claim 4, wherein the fish is salmon.
6. The method of claim 4 or claim 5, wherein the compound or salt thereof is administered orally.
7. Use of a compound or a salt thereof in the preparation of a veterinary composition for controlling sea lice in fish, wherein the compound is a compound of the formula:
8. The use according to claim 7, wherein the fish is salmon.
9. The use according to claim 7 or claim 8, wherein the veterinary composition is administered orally.
10. A composition comprising a compound of the formula: The composition is useful for controlling sea lice in fish.
11. A fish feed premix composition comprising a compound of the following formula or a salt thereof:
12. A medicated fish feed comprising a compound of the following formula or a salt thereof:
